Skip to main content
. 2023 Jan 23;23:42. doi: 10.1186/s12872-023-03069-2

Table 1.

Basic information on CMR patients: control subjects versus HCM; without adverse clinical events versus with combined outcome

Parameters Control subjects (n = 89) HCM population (n = 99) p value HCM patient without adverse clinical events (n = 81) HCM patient with adverse clinical events (n = 18) p value
Baseline and clinical
Age at CMR scan, years 52.74 ± 10.03 55 (46, 65) 0.200 51.85 ± 13.13 67 (62, 69) < 0.001***
Men, n, % 67, 75.28% 71, 71.7% 0.581 61, 75.3% 10, 55.6% 0.092
Family history, n, % 31, 31.3% 50, 61.7% 12, 66.7% 0.695
Body mass index, kg/m2 26.40 (24.51, 28.40) 26.40 ± 3.39 0.821 26.65 ± 3.36 25.28 ± 3.35 0.121
Heart rate, beat/min 68 (64, 75) 66 (58, 68)  < 0.001*** 67 (59, 71) 60.17 ± 7.52 0.026*
Hypertension, n, % 25, 28.1% 62, 62.6%  < 0.001*** 50, 61.7% 12, 66.7% 0.695
Systolic blood pressure, mmHg 150 (125, 180) 150 (123, 180) 159.17 ± 36.81 0.413
Diastolic blood pressure, mmHg 90 (77, 110) 90 (77, 110) 98.28 ± 26.47 0.420
Diabetes mellitus, n, % 15, 16.9% 17, 17.2% 0.954 14, 17.3% 3, 16.7% 1.000
Smoking history, n, % 44, 49.4% 36, 36.4% 0.070 29, 35.8% 7, 38.9% 0.806
CAD, n, % 26, 26.3% 22, 27.2% 4, 22.2% 0.721
PE, n, % 0, 0% 0, 0% 0, 0%
CKD, n, % 1, 1.01% 1, 1.23% 0, 0%

Data were expressed as number (percentage), mean ± standard deviation, or median (interquartile range)

CAD, Coronary atherosclerotic heart disease; PE, Pulmonary embolism; CKD, Chronic Kidney Disease

“*”, “**”, and “***” reflect that the difference between groups is statistically significant

“*” represents p < 0.05; “**” represents p < 0.01; “***” represents p < 0.001